カテゴリー： GBI Research, 医療/バイオ

アルツハイマー病及び関連疾患治療の世界市場

GBI Researchが発行した調査報告書（GBIHC441MR）
◆英語タイトル：Frontier Pharma: Alzheimer’s Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression
◆商品コード：GBIHC441MR
◆発行会社（リサーチ会社）：GBI Research
◆発行日：2017年5月1日
◆ページ数：101
◆レポート形式：英語 / PDF
◆納品方法：Eメール
◆調査対象地域：世界
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD6,995 ⇒換算￥762,455見積依頼/購入/質問フォーム
Site License（同一国内共有可）USD13,990 ⇒換算￥1,524,910見積依頼/購入/質問フォーム
Enterprisewide License（複数国内共有可）USD20,985 ⇒換算￥2,287,365見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGBI Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GBI Research社の概要及び新刊レポートはこちらでご確認いただけます。

 【レポートの概要】

Frontier Pharma: Alzheimer’s Disease and Associated Indications – Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression
Summary

Alzheimer’s disease (AD), the most common form of dementia, is a progressive, neurodegenerative and currently incurable disease characterized by loss of memory and other mental abilities. It has a devastating impact on independence and quality of life, with patients requiring full-time care in the later disease stages. In addition to cognitive impairment, AD is associated with behavioral and psychological changes, which often represent the greatest challenges for patients and caregivers.

The prevalence of AD is escalating rapidly, largely owing to aging populations, as advancing age is the most important epidemiological risk factor for the disease. This will amplify the already substantial societal and economic costs of the disease over the coming years. This has led to high levels of R&D investment over the past two decades, but clinical trial failure rates within the indication are extremely high and treatment options remain limited. There are no disease-modifying therapies for AD, and current approaches can only temporarily slow the worsening of symptoms.

The report focuses on AD alongside four key associated behavioral and psychological indications: anxiety, depression, psychosis and insomnia. These four conditions are highly prevalent in AD and contribute substantially to the disease burden.

Scope

Unmet need is extremely high in AD, with behavioral and psychological complications contributing significantly to the disease burden
– What are the most important etiological risk factors and pathophysiological processes implicated in AD?
– What is the current treatment algorithm?
– How common are anxiety, depression, psychosis and insomnia in AD?
The AD pipeline is large and contains a very high proportion of first-in-class product innovation
– Which molecule types and molecular targets are most prominent across AD and its associated indications?
– What are the connections, in terms of first-in-class innovation, between AD and its associated indications?
– Which first-in-class targets are most promising?
– How does the level of first-in-class innovation differ between products in development for anxiety, depression, psychosis and insomnia?
– How does first-in-class target diversity differ by stage of development and molecular target class?
The deals landscape is active and dominated by G-protein coupled receptor (GPCR)-targeting products
– Which indications attract the highest deal values?
– How has deal activity fluctuated over the past decade?
– Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Reasons to buy

This report will allow you to –
- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, diagnosis and treatment options.
- Identify leading products and key unmet needs within the market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Individual matrix assessments are provided for targets identified in the pipeline for AD, anxiety, depression, psychosis and insomnia. Promising early-stage first-in-class targets are reviewed in greater detail.
- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

【レポートの目次】

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Executive Summary 6
2.1 Limited Treatment Options despite Large Market Opportunity 6
2.2 Exceptionally High Level of First-in-Class Innovation within Alzheimer’s Disease Pipeline 6
2.3 Active Deals Landscape Dominated by GPCR-Targeting Products 6
3 The Case for Innovation 7
3.1 Growing Opportunities for Biologic Products 8
3.2 Diversification of Molecular Targets 8
3.3 Innovative First-in-Class Product Developments Remain Attractive 9
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 9
3.5 Sustained Innovation in Alzheimer’s Disease 10
3.6 GBI Research Report Guidance 10
4 Clinical and Commercial Landscape 12
4.1 Disease Overview 12
4.2 Classification of Dementia and Mild Cognitive Impairment 12
4.3 Symptoms, Disease Staging and Prognosis 13
4.4 Diagnosis 14
4.4.1 Mini Mental State Exam 15
4.4.2 Alzheimer’s Disease Assessment Scale – Cognitive 15
4.4.3 Alzheimer’s Disease Co-operative Study – Activities of Daily Living Inventory 16
4.4.4 Imaging Techniques 16
4.4.5 Lumbar Puncture 17
4.4.6 Blood Tests 17
4.5 Epidemiology 17
4.6 Etiology and Pathophysiology 17
4.6.1 Etiological Risk Factors 17
4.6.2 Pathophysiology 18
4.7 Management and Treatment of Alzheimer’s Disease 21
4.7.1 Pharmacological Intervention 21
4.7.2 Non-pharmacological Intervention 22
4.8 Overview of Marketed Products 23
4.9 Indications Associated with Alzheimer’s Disease 26
4.9.1 Anxiety 26
4.9.2 Depression 27
4.9.3 Psychosis 28
4.9.4 Insomnia 29
5 Assessment of Pipeline Product Innovation 30
5.1 Overview 30
5.2 Pipeline by Stage of Development and Molecule Type 30
5.2.1 Alzheimer’s Disease 30
5.2.2 Alzheimer’s-Disease-Associated Indications 31
5.3 Pipeline by Molecular Target 33
5.3.1 Alzheimer’s Disease 33
5.3.2 Alzheimer’s-Disease-Associated Indications 35
5.4 Comparative Distribution of Programs between the Market and Pipeline by Molecular Target Class 36
5.4.1 Alzheimer’s Disease 36
5.4.2 Alzheimer’s-Disease-Associated Indications 37
5.5 First-in-Class Programs Targeting Novel Molecular Targets 37
5.5.1 Alzheimer’s Disease 37
5.5.2 Alzheimer’s-Disease-Associated Indications 41
5.6 Ratio of First-in-Class Products to First-in-Class Targets 44
5.6.1 Alzheimer’s Disease 44
5.6.2 Alzheimer’s-Disease-Associated Indications 46
5.7 List of All First-in-Class Pipeline Programs 48
6 Signaling Network, Disease Causation and Innovation Alignment 58
6.1 Complexity of Signaling Networks 58
6.2 Signaling Pathways and First-in-Class Molecular Target Integration 58
6.3 First-in-Class Matrix Assessment 59
7 First-in-Class Target Profiles 64
7.1 Pipeline Programs Targeting Presenilin 1 for Alzheimer’s Disease 64
7.2 Pipeline Programs Targeting Apolipoprotein E for Alzheimer’s Disease 65
7.3 Pipeline Programs Targeting Apoptosis Regulator BAX for Alzheimer’s Disease 66
7.4 Pipeline Programs Targeting Sortilin for Alzheimer’s Disease 69
7.5 Pipeline Programs Targeting Metabotropic Glutamate Receptors 1, 2, 3, 4, 5 and 7 for Alzheimer’s Disease, Anxiety, Depression and Psychosis 70
7.6 Pipeline Programs Targeting Sodium Dependent Neutral Amino Acid Transporter B(0) AT2 for Depression and Anxiety 76
7.7 Pipeline Programs Targeting Cytochrome P450 1A2 for Insomnia and Anxiety 78
8 Strategic Consolidations 80
8.1 Industry-Wide First-in-Class Deals 80
8.2 Licensing Deals 82
8.2.1 Deals by Region, Value and Year 82
8.2.2 Deals by Indication 83
8.2.3 Deals by Stage of Development and Value 83
8.2.4 Deals by Molecule Type, Molecular Target and Value 84
8.2.5 List of Deals with Deal Values Exceeding $100m 86
8.3 Co-development Deals 87
8.3.1 Deals by Region, Value and Year 87
8.3.2 Deals by Indication 88
8.3.3 Deals by Stage of Development and Value 88
8.3.4 Deals by Molecule Type, Molecular Target and Value 89
8.3.5 List of Deals with Deal Values Exceeding $100m 90
8.4 First-in-Class Programs with and without Prior Involvement in Licensing and Co-development Deals 90
9 Appendix 91
9.1 References 91
9.2 Abbreviations 98
9.3 Research Methodology 99
9.3.1 Data integrity 99
9.3.2 Innovative and meaningful analytical techniques and frameworks: 99
9.3.3 Evidence based analysis and insight: 99
9.4 Secondary Research 99
9.4.1 Market Analysis 99
9.4.2 Pipeline Analysis 99
9.4.3 First-in-Class Matrix Assessment 100
9.4.4 First-in-Class Target Profiles 100
9.4.5 Licensing and Co-Development Deals 101
9.5 Contact Us 101
9.6 Disclaimer 101

1.1 List of Tables
Table 1: Alzheimer’s Disease and Associated Indications, Global, Common Forms of Dementia, 2017 13
Table 2: Alzheimer’s Disease and Associated Indications, Global, Common Alzheimer’s Disease Symptoms by Disease Stage, 2017 14
Table 3: Alzheimer’s Disease and Associated Indications, Global, Scoring for Mini-Mental State Exam, 2017 15
Table 4: Alzheimer’s Disease and Associated Indications, Global, Scoring for the Alzheimer’s Disease Assessment Scale-Cognitive , 2017 16
Table 5: Alzheimer’s Disease and Associated Indications, Global, Common Physical and Psychological Symptoms Associated with Anxiety Disorders, 2017 26
Table 6: Alzheimer’s Disease and Associated Indications, Global, Common Forms of Depression, 2017 28
Table 7: Alzheimer’s Disease and Associated Indications, Global, Key Features of Presenilin 1, 2017 64
Table 8: Alzheimer’s Disease and Associated Indications, Global, Pipeline Programs Targeting Presenilin 1, 2017 65
Table 9: Alzheimer’s Disease and Associated Indications, Global, Key Features of Apolipoprotein E, 2017 66
Table 10: Alzheimer’s Disease and Associated Indications, Global, Pipeline Programs Targeting Apolipoprotein E, 2017 66
Table 11: Alzheimer’s Disease and Associated Indications, Global, Key Features of Apoptosis Regulator BAX, 2017 68
Table 12: Alzheimer’s Disease and Associated Indications, Global, Pipeline Programs Targeting Apoptosis Regulator BAX, 2017 68
Table 13: Alzheimer’s Disease and Associated Indications, Global, Key Features of Sortilin, 2017 69
Table 14: Alzheimer’s Disease and Associated Indications, Global, Pipeline Programs Targeting Sortilin, 2017 70
Table 15: Alzheimer’s Disease and Associated Indications, Global, Key Features of Metabotropic Glutamate Receptor 1, 2017 71
Table 16: Alzheimer’s Disease and Associated Indications, Pipeline Programs Targeting Metabotropic Glutamate Receptor 1, 2017 71
Table 17: Alzheimer’s Disease and Associated Indications, Global, Key Features of Metabotropic Glutamate Receptor 2, 2017 72
Table 18: Alzheimer’s Disease and Associated Indications, Pipeline Programs Targeting Metabotropic Glutamate Receptor 2, 2017 72
Table 19: Alzheimer’s Disease and Associated Indications, Global, Key Features of Metabotropic Glutamate Receptor 3, 2017 73
Table 20: Alzheimer’s Disease and Associated Indications, Pipeline Programs Targeting Metabotropic Glutamate Receptor 3, 2017 73
Table 21: Alzheimer’s Disease and Associated Indications, Global, Key Features of Metabotropic Glutamate Receptor 4, 2017 74
Table 22: Alzheimer’s Disease and Associated Indications, Pipeline Programs Targeting Metabotropic Glutamate Receptor 4 (GRM4), 2017 74
Table 23: Alzheimer’s Disease and Associated Indications, Global, Key Features of Metabotropic Glutamate Receptor 5, 2017 75
Table 24: Alzheimer’s Disease and Associated Indications, Pipeline Programs Targeting Metabotropic Glutamate Receptor 5, 2017 75
Table 25: Alzheimer’s Disease and Associated Indications, Global, Key Features of Metabotropic Glutamate Receptor 7 (GRM7), 2017 76
Table 26: Alzheimer’s Disease and Associated Indications, Pipeline Programs Targeting Metabotropic Glutamate Receptor 7 (GRM7), 2017 76
Table 27: Alzheimer’s Disease and Associated Indications, Global, Sodium Dependent Neutral Amino Acid Transporter B0 AT2, 2017 77
Table 28: Alzheimer’s Disease and Associated Indications, Global, Pipeline Programs Targeting Sodium Dependent Neutral Amino Acid Transporter B0 AT2, 2017 78
Table 29: Alzheimer’s Disease and Associated Indications, Global, Key Features of Cytochrome P450 1A2, 2017 79
Table 30: Alzheimer’s Disease and Associated Indications, Global, Pipeline Programs Targeting Cytochrome P450 1A2, 2017 79

1.2 List of Figures
Figure 1: Alzheimer’s Disease and Associated Indications, Global, US, Innovation Trends in Product Approvals, 1987-2014 8
Figure 2: Alzheimer’s Disease and Associated Indications, US, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006-2013 9
Figure 3: Alzheimer’s Disease and Associated Indications, Global, Alzheimer’s Disease Market by Molecular Target, 2017 24
Figure 4: Alzheimer’s Disease and Associated Indications, Global, Alzheimer’s Disease Associated Indications Market by Molecular Target, 2017 25
Figure 5: Alzheimer’s Disease and Associated Indications, Global, Pipeline by Therapy Area, 2017 30
Figure 6: Alzheimer’s Disease, Global, Pipeline by Stage of Development and Molecule Type, 2017 31
Figure 7: Anxiety, Depression, Psychosis and Insomnia, Global, Pipelines by Stage of Development, 2017 32
Figure 8: Anxiety, Depression, Psychosis and Insomnia, Global, Pipelines by Molecule Type, 2017 33
Figure 9: Alzheimer’s Disease, Global, Pipeline by Molecular Target, 2017 34
Figure 10: Anxiety, Depression, Psychosis and Insomnia, Global, Pipelines by Molecular Target, 2017 36
Figure 11: Alzheimer’s Disease, Global, Pipeline and Marketed Products by Molecular Target Class, 2017 37
Figure 12: Alzheimer’s-Disease-Associated Indications, Global, Pipeline and Marketed Products by Molecular Target Class, 2017 37
Figure 13: Alzheimer’s Disease, Global, Pipeline by Molecular Target Class, First-in-Class Status and Stage of Development, 2017 39
Figure 14: Alzheimer’s Disease, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Stage of Development and Molecular Target Class, 2017 40
Figure 15: Alzheimer’s-Disease-Associated Indications, Global, Pipeline by Molecular Target Class, First-in-Class Status and Stage of Development, 2017 42
Figure 16: Alzheimer’s-Disease-Associated Indications, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Stage of Development and Molecular Target Class, 2017 43
Figure 17: Alzheimer’s Disease, Global, Ratio of First-in-Class Products to First-in-Class Targets for Pipeline Products by Stage of Development and Molecular Target Class, 2017 45
Figure 18: Alzheimer’s-Disease-Associated Indications, Global, Ratio of First-in-Class Products to First-in-Class Targets for Pipeline Products by Stage of Development and Molecular Target Class, 2017 47
Figure 19: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 1) 48
Figure 20: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 2) 49
Figure 21: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 3) 50
Figure 22: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 4) 51
Figure 23: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 5) 52
Figure 24: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 6) 53
Figure 25: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 7) 54
Figure 26: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 8) 55
Figure 27: Alzheimer’s Disease and Associated Indications, Global, List of All First-in-Class Pipeline Programs, 2017 (part 9) 56
Figure 28: Alzheimer’s Disease and Associated Indications, Global, List of All Pipeline Programs, 2017 (part 10) 57
Figure 29: Alzheimer’s Disease and Associated Indications, Global, First-in-Class Matrix Assessment for Alzheimer’s Disease Products, 2017 60
Figure 30: Alzheimer’s Disease and Associated Indications, Global, First-in-Class Matrix Assessment for Anxiety Products, 2017 61
Figure 31: Alzheimer’s Disease and Associated Indications, Global, First-in-Class Matrix Assessment for Depression Products, 2017 62
Figure 32: Alzheimer’s Disease and Associated Indications, Global, First-in-Class Matrix Assessment for Psychosis Products, 2017 62
Figure 33: Alzheimer’s Disease and Associated Indications, Global, First-in-Class Matrix Assessment for Insomnia Products, 2017 63
Figure 34: Alzheimer’s Disease and Associated Indications, Global, Industry-Wide Licensing Deals by First-in-Class Status and Stage of Development, 2006-2014 80
Figure 35: Alzheimer’s Disease and Associated Indications, Global, Industry-Wide Licensing Deals by Deal Value, Upfront Payment Value, Stage of Development and First-in-Class Status, 2006-2014 81
Figure 36: Alzheimer’s Disease and Associated Indications, Global, Licensing Deals by Region, Value and Year, 2006-2017 82
Figure 37: Alzheimer’s Disease and Associated Indications, Global, Licensing Deals by Indication and Deal Value, 2006-2017 83
Figure 38: Alzheimer’s Disease and Associated Indications, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006-2017 84
Figure 39: Alzheimer’s Disease and Associated Indications, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type, 2006-2017 84
Figure 40: Alzheimer’s Disease and Associated Indications, Global, Number and Aggregate Deal Value of Licensing Deals by Molecular Target, 2006-2017 85
Figure 41: Alzheimer’s Disease and Associated Indications, Global, Licensing Deals Exceeding $100m in Value, 2006-2017 86
Figure 42: Alzheimer’s Disease and Associated Indications, Global, Co-development Deals by Region, Value and Year, 2006-2017 87
Figure 43: Alzheimer’s Disease and Associated Indications, Global, Co-development Deals by Indication and Deal Value, 2006-2017 88
Figure 44: Alzheimer’s Disease and Associated Indications, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017 88
Figure 45: Alzheimer’s Disease and Associated Indications, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type, 2006-2017 89
Figure 46: Alzheimer’s Disease and Associated Indications, Global, Number and Aggregate Deal Value of Co-development Deals by Molecular Target, 2006-2017 89
Figure 47: Alzheimer’s Disease and Associated Indications, Global, Co-development Deals Exceeding $100m in Value, 2006-2017 90

【免責事項】
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ アルツハイマー病及び関連疾患治療の世界市場(Frontier Pharma: Alzheimer’s Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 慢性閉塞性肺疾患（COPD）治療薬の世界市場：画期的医薬品の市場機会及び商用化 Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) - Identifying and Commercializing First-in-Class Innovation Summary Chronic Obstructive Pulmonary Disease (COPD) is a progressive disorder associated with chronic inflammation of the airways and lungs. Persistent breathing difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of morbidity and the fifth-leading cause of death in the world. COPD is linked to cumulative exposure to risk factors, primarily tobacco smoke, but also environmental pollutants. The COPD marketed products landscape consists of pharmacological therapies aimed at managing the symptoms associated with COPD, although none of the available therapies have...
  • 喘息治療薬の世界市場：画期的医薬品の市場機会及び商用化 Frontier Pharma: Asthma - Identifying and Commercializing First-in-Class Innovation Summary Large and Innovative Pipeline Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. More pertinently, the degree and proportion of breakthrough innovations is significant. GBI Research analysis identified 59 first-in-class programs in the asthma pipeline, acting on 43 first-in-class molecular targets, accounting for 23% of all products with a disclosed molecular target and reflective of the high degree...
  • 精神分裂病および関連疾患治療薬の世界市場 Frontier Pharma: Schizophrenia and Associated Indications - Small but Diverse Range of First-in-Class Molecular Targets Hold Promise for Treatment of Negative and Cognitive Symptoms Summary Schizophrenia is a severe mental disorder that is characterized by abnormal social behavior and failure to recognize what is real; its symptoms are broadly divided into positive, negative and cognitive. The treatment of schizophrenia is multi-factorial and includes medical, psychological and psychosocial inputs. Antipsychotic medication is the main pharmacological agent used, along with counselling, job training, and social rehabilitation. Both typical and atypical antipsychotics are used, and the choice of medication is usually left to...
  • 疼痛（Pain）治療薬の世界市場：画期的医薬品の市場機会及び商用化 Frontier Pharma: Pain - Identifying and Commercializing First-in-Class Innovation Summary Large and Innovative Pipeline The active pain pipeline is populated by 796 products across all stages of development, which exhibit a highly diverse range of molecular targets. GBI Research’s analyses identified 122 first-in-class programs in active development, constituting 13.6% of the pipeline and acting on 65 first-in-class molecular targets, indicating a high degree of innovation. This is in stark contrast to the pain therapeutics market, which has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established active...
  • 非ホジキンリンパ腫（NHL）治療薬の世界市場：革新的なライセンシング機会 Frontier Pharma: Innovative Licensing Opportunities in Non-Hodgkin Lymphoma Summary Non-Hodgkin Lymphoma (NHL) can be seen as a collection of up to 60 smaller subtypes of malignant lymphoid disease, defined by distinct morphological, cytogenetic and immunophenotypic characteristics that can be broadly classified as either indolent or aggressive disease. The slow growing nature of the former means that first-line treatment for diagnosed patients can be delayed, an option not commonly recommended for aggressive disease. Across both indolent and aggressive disease, first-line chemotherapy in combination with the blockbuster drug rituxumab can induce high rates of response, and prolonged durations of remission. Despite this,...
  • Frontier Pharma：脂肪肝治療の世界市場 Frontier Pharma: Fatty Liver Disease - High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products Summary Fatty liver disease (FLD) comprises a spectrum of chronic liver disorders characterized by excessive lipid accumulation in the liver (steatosis), which may lead to inflammation (steatohepatitis) and fibrosis. It has the potential to progress to end-stage liver diseases such as cirrhosis, liver cancer and liver failure, and is also associated with numerous complications and co-morbidities, including cardiovascular and metabolic diseases. FLD can be divided into non-alcoholic FLD (NAFLD) and alcoholic FLD (AFLD), depending on the patent’s history of alcohol use. FLD is...
  • 膵臓癌治療薬の世界市場：画期的医薬品の市場機会及び商用化 Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation Summary Pancreatic cancer is the 12th most common cancer globally, and the fourth most fatal, with a mortality rate of 10.9 deaths per 100,000 people per year. The poor prognosis of pancreatic cancer patients has highlighted a significant need for new and improved approaches to treatment, which is not being met by the current market. A highly active pancreatic cancer pipeline contains an array of products with varying molecule types and mechanisms of action, which provides a striking contrast to the current, chemotherapy dominated, market. Within the pipeline, there are...
  • リウマチ性関節炎治療薬の世界市場 Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation Summary Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable auto-immune disease that affects the joints, and is characterized by synovial inflammation and hyperplasia. It occurs when a number of aberrant cell signaling events trigger chronic inflammation of the synovium - the soft tissue of the joint - leading to pain, joint stiffness, and eventually deformity and disability. With the disease affecting 0.3-1.0% of the global population, the societal and economic costs of RA are substantial. The large target patient population and the relatively high...
  • 眼科用治療薬の世界市場 Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way Summary The visual system, including the eye and its surrounding structures, can be affected by a number of pathological conditions. Ophthalmology encompasses a diverse range of indications affecting this system. Key diseases within this therapy area include glaucoma, age-related macular degeneration, diabetic macular edema, diabetic retinopathy and dry eye syndrome. While treatments for dry eye syndrome are generally able to control its symptoms in the majority of patients, the other four diseases are progressive, chronic,...
  • 卵巣がん治療薬の世界市場：画期的医薬品の市場機会及び商用化 Frontier Pharma: Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation Summary Ovarian cancer is the sixth most common cancer in females and it also has the highest mortality rate of gynecological cancers. The five-year survival rate is approximately 45%, although the disease is ultimately fatal in the majority of patients due to a high rate of recurrence. Surgery is generally considered an effective treatment for localized tumors, however the management of recurrent and later-stage disease is largely reliant on cytotoxic chemotherapy regimens. A highly active ovarian cancer pipeline contains an array of diverse molecule types and molecular targets, in contrast...
  • 乳がん治療薬の世界市場：ファーストインクラス革新 Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes Summary The breast cancer pipeline is the largest in the pharmaceutical industry, with 1,050 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. The degree and proportion of breakthrough innovations in this pipeline is exceptional – GBI Research analysis identified 333 first-in-class programs in the breast cancer pipeline, acting on 251 first-in-class molecular targets. This accounts for some 39% of all products with a disclosed molecular target,...
  • 糖尿病合併症治療薬の世界市場 Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies Summary Diabetes is a common long-term condition that can lead to a range of disparate and serious complications. It is a lifelong, multi-systemic condition that affects a number of integral organs. Diabetes has a rapidly increasing prevalence – it currently affects 10% of adults globally, and is estimated to become the seventh-leading cause of death by 2030. The lack of absolute treatment for the condition and the difficulty in maintaining constant glycemic control, even following adequate treatment, can result in a...
  • パーキンソン病治療薬の世界市場：画期的医薬品の市場機会及び商用化 Frontier Pharma: Parkinson’s Disease - Identifying and Commercializing First-in-Class Innovation Summary Parkinson’s Disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease, affecting around 7.4 million people worldwide. It is caused by the progressive loss of dopamine-producing neurons in the substantia nigra within the basal ganglia. The main motor symptoms are tremors, bradykinesia and rigidity, although symptoms vary between individuals. As the disease progresses to more advanced stages, increasing symptoms and complications develop, which can cause severe disability in patients. The current market offers a number of anti-PD treatment options which provide symptomatic relief. Levodopa is currently the...
  • 胃がん治療薬の世界市場 Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs Summary Gastric cancer is the fifth most common cancer globally, and due to its indolent nature remains one of the most common causes of cancer-related death worldwide. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The gastric cancer market is undergoing a gradual change, from a focus on generic chemotherapy regimens to complex treatment landscape based on targeted therapies. Recently the market has witnessed the approval of efficacious therapies such as Cyramza, but this only...
  • 慢性痛・急性痛・神経因性痛治療薬の世界市場 Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes Summary Pain, and in particular chronic pain, is a significant global health issue. While pain is not considered a disease in its own right, there is a growing body of evidence that substantiates chronic pain as a disease, rather than just as a symptom of a primary cause. In the US, pain affects more people than cancer, diabetes and heart disease combined, with an estimated 100 million people having experienced at least one chronic pain episode in the last 12...

    • ◆H&Iグローバルリサーチのお客様（例）◆